1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Aprogen Biologics

Aprogen Biologics

KKRX:003060
1,387.00
KRW
-21.00
(-1.49%)
-5,425.24EPS
27.21BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
36,521.99
36,356.85
38,989.43
41,228.35
43,184.12
34,181.96
31,335.63
18,895.06
15,884.32
18,216.86
15,786.46
8,034.85
5,555.91
6,440.76
Basic EPS, GAAP
-25,777.7
-4,270.86
2,669.29
-3,660.74
-15,329.34
-915.19
-5,118.37
3,987.69
2,278.68
3,531.96
-21,371.14
-12,518.74
-12,923.54
-5,851.49
Free Cash Flow per Basic Share
-14,096.91
-10,011.26
-5,499.39
-2,214.84
-10,844.45
-687.42
-1,051
2,362.47
-2,156.66
6,757.72
-11,211.74
-5,538.96
-3,642.85
-2,711.4
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
63,620.01
61,424.17
65,528.5
75,827.28
69,226.91
106,406.32
102,308.05
144,470.57
145,197.71
82,962.59
63,885.25
28,721.23
15,765.33
14,739.56
Tangible Book Value per Share
61,388.46
59,292.25
61,622.47
71,212.39
66,098.9
104,080.05
100,850.78
143,431.42
144,398.34
81,706.42
62,803.86
28,333.02
15,364.91
14,464.14
Basic Weighted Avg Shares
1
1
1
1
1
1
2
3
4
4
6
8
13
13
Sales/Revenue/Turnover
29,543
33,092
40,324
44,122
46,101
45,395
50,904
53,320
56,482
65,190
87,364
67,378
73,226
86,181
Operating Margin (%)
-45.87
-16.17
-2.15
-0.56
-3.16
-1.82
-3.79
-1.82
-6.97
-5.33
-66.15
-79.13
-82.6
-55.3
Depreciation Expense
790
1,387
1,599
1,428
1,675
1,466
1,661
1,932
2,072
2,404
21,398
19,090
19,185
19,411
Net Income, GAAP
-20,852
-3,887
2,761
-3,918
-16,365
-1,215
-8,315
11,253
8,103
12,639
-118,270
-104,979
-170,331
-78,296
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
6.91
8.47
- -
- -
- -
- -
Profit Margin (%)
-70.58
-11.75
6.85
-8.88
-35.5
-2.68
-16.33
21.1
14.35
19.39
-135.38
-155.81
-232.61
-90.85
Working Capital
33,860
38,183
39,252
37,919
32,038
25,244
202,731
327,848
344,025
79,502
-73,081
-32,308
-74,604
-89,123
LT Debt
8,332
8,395
4,139
1,080
24,894
- -
228
164
120
129
50,277
48,197
58,675
50,492
Total Equity
56,547
62,113
67,745
78,120
76,814
150,511
347,637
598,356
597,181
510,411
368,691
378,691
277,567
267,710
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-0.59
-0.8
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
1.18
1.91
- -
- -
- -
- -
Return on Common Equity (%)
-33.43
-6.56
4.2
-5.24
-20.82
-1.07
-4.19
2.99
1.6
2.71
-29.75
-28.1
-58.11
-33.9

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
170,121
174,277
160,345
LT Borrowings
40,000
38,000
36,000
LT Finance Leases
18,675
14,878
14,492
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
102,592
58,313
27,213

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
154,529
151,945
117,753
Cash, Cash Equivalents & STI
51,633
50,102
22,698
Accounts Receivable, Net
15,663
14,814
14,716
Inventories
51,601
56,150
45,242
Total Current Liabilities
229,133
226,640
206,875
Payables & Accruals
- -
- -
- -
ST Debt
170,121
174,277
160,345
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.62%
-13.3%
-26.7%
Free Cash Flow
-117.42%
-201.74%
3.37%
Net Income, GAAP
-62.47%
-191.35%
62.25%
Sales/Revenue/Turnover
7.04%
8.23%
8.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,606
15,192
14,531
22,049
67,378
2025
16,848
14,896
21,118
20,364
73,226
2026
21,620
23,078
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1,041.98
-5,187.41
-1,364.32
-4,555.7
-12,518.74
2025
-3,264.17
-5,078.48
-1,849.66
-2,736.87
-12,923.54
2026
-295.33
-999
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeong-Chool Kim
Full Time Employees
445
Sector
Health technology
Industry
Pharmaceuticals: major
Address
6, 31, Ogeum-ro 19-gil Seoul SL South Korea
IPO Date
Oct 19, 1984
Website
aprogen-pharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Aprogen Biologics Inc. (003060.KS) manufactures and sells pharmaceutical and biopharmaceutical products in South Korea. The company produces synthetic pharmaceuticals including circulatory system drugs, central nervous system drugs, digestive system drugs, antibiotics, anti-biotic, anti-fungal, anti-viral, and anti-ulcerant products; biopharmaceuticals such as biosimilars, recombinant proteins, and novel biologics including biosimilar versions of Remicade, Herceptin, and Rituxan, alongside pipelines like AP102 and AP202 for blood vessel diseases and tumors; external agents, anti-cancer drugs, amino-acid nutrient transfusion agents, anti-allergy medications, osteoarthritis treatments, skeletal muscle relaxants, NSAIDs, osteoporosis drugs, endocrine products, and cosmetics. Founded in 1960 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, with additional facilities in Cheongju-si, Chungcheongbuk-do, Aprogen Biologics operates primarily in the domestic market through its pharmaceutical and bio business divisions, serving healthcare providers and patients with over 200 medical products. In recent developments, the company received KRW 15 billion in funding from APTN Inc. in October 2025; completed production of clinical drug materials for a new degenerative arthritis treatment in September 2025 using its biopharmaceutical facilities; and underwent a corporate restructuring in December 2022 when Aprogen Pharmaceuticals Inc. acquired Aprogen Biologics from Aprogen Inc., alongside a 6.87% stake sale to an undisclosed buyer in July 2024 for KRW 43.9 billion.